Chikungunya virus is a mosquito-borne alphavirus and the causative agent of chikungunya disease which has low mortality but high acute and chronic morbidity resulting in a high overall burden of disease. An important public health impact of vaccination is to decrease burden of disease and economic losses in areas impacted by the virus, and prevent or reduce chronic morbidity associated with chikungunya. The chikungunya vaccine value profile (VVP) provides a high-level holistic assessment of the information and available data to inform the potential public health, economic, and societal value of chikungunya vaccines in the development pipeline.
This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the chikungunya VVP and collectively aimed to identify current research and knowledge gaps. View the in-press Vaccine article below.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.